×
About 535 results

ALLMedicine™ Skin Fragility Center

Research & Reviews  184 results

Epidermolysis Bullosa Simplex - GeneReviews® - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/n/gene/ebs/

Aug 4th, 2022 - Epidermolysis bullosa simplex (EBS) is characterized by fragility of the skin (and mucosal epithelia in some instances) that results in non-scarring blisters and erosions caused by minor mechanical trauma. EBS is distinguished from other types of ...

Topical gene therapy for dystrophic epidermolysis bullosa shows promise
https://www.mdedge.com/dermatology/article/256461/pediatrics/topical-gene-therapy-dystrophic-epidermolysis-bullosa-shows
Doug Brunk

Jul 25th, 2022 - INDIANAPOLIS – An investigational topical treatment for dystrophic epidermolysis bullosa (DEB) known as beremagene geperpavec (B-VEC) showed durable and statistically significant improvement in complete wound healing at 3 and 6 months compared wit.

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure
https://clinicaltrials.gov/ct2/show/NCT03126539

Jun 30th, 2022 - The primary purpose of the study is to compare the expression of keratins before and after application of sulforaphane (SF) and determine whether these findings alter skin fragility seen in both intrinsic and extrinsic skin aging as well as in ult...

Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic ...
https://doi.org/10.1016/j.ymthe.2022.06.005
Molecular Therapy : the Journal of the American Society O... Hong SA, Kim SE et. al.

Jun 13th, 2022 - Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin fragility disorder caused by loss-of-function mutations in the COL7A1 gene, which encodes type VII collagen (C7), a protein that functions in skin adherence. From 36 Korean RDEB pa...

International Perspectives on Joint Hypermobility: A Synthesis of Current Science to Gu...
https://doi.org/10.1097/RHU.0000000000001864
Journal of Clinical Rheumatology : Practical Reports on R... Nicholson LL, Simmonds J et. al.

Jun 7th, 2022 - There is exponential clinical and research interest in joint hypermobility due to recognition of the complexity of identification, assessment, and its appropriate referral pathways, ultimately impacting management. This state-of-the-science review...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  13 results

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure
https://clinicaltrials.gov/ct2/show/NCT03126539

Jun 30th, 2022 - The primary purpose of the study is to compare the expression of keratins before and after application of sulforaphane (SF) and determine whether these findings alter skin fragility seen in both intrinsic and extrinsic skin aging as well as in ult...

Genetics of Ehlers-Danlos Syndrome
https://clinicaltrials.gov/ct2/show/NCT03093493

Apr 28th, 2022 - Ehlers-Danlos Syndrome (EDS) is a genetic disease that affects collagen synthesis and structure resulting in multisystem connective tissue involvement with twelve different subtypes. The clinical manifestations of EDS include skin hyperextensibili...

Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa.
https://clinicaltrials.gov/ct2/show/NCT05288478

Apr 14th, 2022 - Inherited Epidermolysis Bullosa (EB) is a group of genetic disorders with skin fragility and blistering. In addition to the skin, it can affect the mucous membranes, causing oral symptoms including oral pain and discomfort due to recurrent oral bl...

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
https://clinicaltrials.gov/ct2/show/NCT03068780

Mar 17th, 2022 - This is a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB). EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In...

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
https://clinicaltrials.gov/ct2/show/NCT02810951

Oct 19th, 2021 - RDEB is a rare skin and connective tissue disease characterized clinically by skin fragility with easy blistering, erosion and scarring of skin and mucous membranes, and caused by the deficiency of the protein type VII collagen (COL7). The objecti...

see more →

News  16 results

Topical gene therapy for dystrophic epidermolysis bullosa shows promise
https://www.mdedge.com/dermatology/article/256461/pediatrics/topical-gene-therapy-dystrophic-epidermolysis-bullosa-shows
Doug Brunk

Jul 25th, 2022 - INDIANAPOLIS – An investigational topical treatment for dystrophic epidermolysis bullosa (DEB) known as beremagene geperpavec (B-VEC) showed durable and statistically significant improvement in complete wound healing at 3 and 6 months compared wit.

Topical Gene Therapy for Dystrophic Epidermolysis Bullosa Shows Promise
https://www.medscape.com/viewarticle/977903

Jul 25th, 2022 - INDIANAPOLIS – An investigational topical treatment for dystrophic epidermolysis bullosa (DEB) known as beremagene geperpavec (B-VEC) showed durable and statistically significant improvement in complete wound healing at 3 and 6 months compared wit...

Despite New Ichthyosis Treatment Recommendations, 'Many Questions Still Exist'
https://www.medscape.com/viewarticle/949188

Apr 13th, 2021 - For as many disorders of cornification and types of ichthyosis that have been shown to benefit from retinoids, a seemingly equal number have no data or show no improvement. According to a consensus statement published in the February issue of Pedi...

Despite new ichthyosis treatment recommendations, ‘many questions still exist’
https://www.mdedge.com/dermatology/article/238473/pediatrics/despite-new-ichthyosis-treatment-recommendations-many
Doug Brunk

Apr 12th, 2021 - For as many disorders of cornification and types of ichthyosis that have been shown to benefit from retinoids, a seemingly equal number have no data or show no improvement. Dr.

IV gentamicin improves epidermolysis bullosa
https://www.mdedge.com/dermatology/article/225876/rare-diseases/iv-gentamicin-improves-epidermolysis-bullosa
Bruce Jancin

Jul 22nd, 2020 - In a pilot study, intravenous gentamicin improved wound closure and quality of life while dampening disease activity in patients with recessive dystrophic epidermolysis bullosa attributable to nonsense mutations, Michelle Hao said at the virtual a.

see more →